Growth Hormone Deficiency in Children, Growth Hormone Disorder
Conditions
Brief summary
This trial is conducted in Europe and Asia. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of a single dose of long-acting growth hormone (NNC0195-0092, somapacitan) compared to daily dosing of Norditropin® SimpleXx® (somatropin) in children with growth hormone deficiency.
Interventions
DRUGsomapacitan
A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order. Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation.
DRUGsomatropin
Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 13 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH (growth hormone) stimulation tests, peak GH level below or equal to 7.0 ng/ml. For children with three or more pituitary hormone deficiencies only one GH stimulation test will be needed. If in accordance with country specific practice, growth hormone deficiency can be defined by only one GH stimulation test, peak GH level below or equal to 7.0 ng/ml. * Pre-pubertal children at screening. Boys: Tanner stage 1 and age above or equal to 6 years and below 13 years. Girls: Tanner stage 1 and age above or equal to 6 years and below 12 years * Body weight above or equal to 16.0 kg and below or equal to 50.0 kg * Stable GH replacement treatment for at least 3 months
Exclusion criteria
* History or presence of malignancy * Overt diabetes mellitus (fasting blood glucose above or equal to 7.0 mmol/l)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (AEs) | From first administration of trial product and up until day 35 (final visit) |
Secondary
| Measure | Time frame |
|---|---|
| The area under the insulin-like growth factor I (IGF-I) concentration-time curve | From 0 to 168 hours after dosing |
Countries
Austria, Belgium, France, Israel, North Macedonia, Norway, Slovenia, Spain, Sweden, Switzerland
Outcome results
None listed